Correlation Between Mineralys Therapeutics, and Stoke Therapeutics

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Stoke Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Stoke Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Stoke Therapeutics, you can compare the effects of market volatilities on Mineralys Therapeutics, and Stoke Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Stoke Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Stoke Therapeutics.

Diversification Opportunities for Mineralys Therapeutics, and Stoke Therapeutics

0.67

Correlation Coefficient

Mineralys Therapeutics,  Stoke Therapeutics

Poor diversification

The 3 months correlation between Mineralys and Stoke is 0.67. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Stoke Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Stoke Therapeutics and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Stoke Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Stoke Therapeutics has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Stoke Therapeutics go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Stoke Therapeutics

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.86 times more return on investment than Stoke Therapeutics. However, Mineralys Therapeutics, Common is 1.16 times less risky than Stoke Therapeutics. It trades about -0.11 of its potential returns per unit of risk. Stoke Therapeutics is currently generating about -0.1 per unit of risk. If you would invest  1,277  in Mineralys Therapeutics, Common on November 28, 2024 and sell it today you would lose (352.00) from holding Mineralys Therapeutics, Common or give up 27.56% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Stoke Therapeutics

Mineralys Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Stoke Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Stoke Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in March 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Mineralys Therapeutics, and Stoke Therapeutics

The main advantage of trading using opposite Mineralys Therapeutics, and Stoke Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Stoke Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stoke Therapeutics will offset losses from the drop in Stoke Therapeutics' long position.

The idea behind Mineralys Therapeutics, Common and Stoke Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.